Salbutamol

Overview

Salbutamol, also known as albuterol and sold under the brand name Ventolin among others, is a medication that opens up the medium and large airways in the lungs. It is a short-acting β₂ adrenergic receptor agonist that causes relaxation of airway smooth muscle. It is used to treat asthma, including asthma attacks and exercise-induced bronchoconstriction, as well as chronic obstructive pulmonary disease (COPD). It may also be used to treat high blood potassium levels. Salbutamol is usually used with an inhaler or nebuliser, but it is also available in a pill, liquid, and intravenous solution. Onset of action of the inhaled version is typically within 15 minutes and lasts for two to six hours.[1–4] WP

Common side effects include shakiness, headache, fast heart rate, dizziness, and feeling anxious. Serious side effects may include worsening bronchospasm, irregular heartbeat, and low blood potassium levels. Its use during pregnancy and breastfeeding is widespread and no evidence exists to suggest it is unsafe.[2][5] WP

Salbutamol was patented in 1966 in Britain and became commercially available in the United Kingdom in 1969. It was approved for medical use in the United States in 1982. It is on the World Health Organization's List of Essential Medicines. Salbutamol is available as a generic medication. In 2023, it was the seventh most commonly prescribed medication in the United States, with 59 million prescriptions.[2][6–10] WP

Uses, dosage and effects

Medical uses

Salbutamol is typically used to treat bronchospasm (due to any cause—allergic asthma or exercise-induced), as well as chronic obstructive pulmonary disease. It is also one of the most common medicines used in rescue inhalers (short-term bronchodilators to alleviate asthma attacks).[2][11] WP

As a β₂ agonist, salbutamol also has use in obstetrics. Intravenous salbutamol can be used as a tocolytic to relax the uterine smooth muscle to delay premature labour. While preferred over agents such as atosiban and ritodrine, its role has largely been replaced by the calcium channel blocker nifedipine, which is more effective and better tolerated.[12] WP

Salbutamol has been used to treat acute hyperkalemia, as it stimulates potassium flow into cells, thus lowering the potassium in the blood.[3] WP

Two recent studies have suggested that salbutamol reduces the symptoms of newborns and adolescents with myasthenia gravis and transient neonatal myasthenia gravis.[13][14] WP

Veterinary use

Salbutamol's low toxicity makes it safe for other animals and thus is the medication of choice for treating acute airway obstruction in most species. It is usually used to treat bronchospasm or coughs in cats and dogs and used as a bronchodilator in horses with recurrent airway obstruction; it can also be used in emergencies to treat asthmatic cats.[15][16][17] WP

Toxic effects require an extremely high dose, and most overdoses are due to dogs chewing on and puncturing an inhaler or nebuliser vial.[18] WP

Risks and side effects

Adverse effects

The most common side effects are fine tremor, anxiety, headache, muscle cramps, dry mouth, and palpitation. Other symptoms may include tachycardia, arrhythmia, flushing of the skin, myocardial ischemia (rare), and disturbances of sleep and behaviour. Rarely occurring, but of importance, are allergic reactions of paradoxical bronchospasms, urticaria (hives), angioedema, hypotension, and collapse. High doses or prolonged use may cause hypokalemia, which is of concern especially in patients with kidney failure and those on certain diuretics and xanthine derivatives.[19] WP

Salbutamol metered dose inhalers have been described as the "single biggest source of carbon emissions from NHS medicines prescribing" due to the propellants used in the inhalers. Dry powder inhalers are recommended as a low-carbon alternative.[20] WP

Misuse

Albuterol and other beta-2 adrenergic agonists are used by some recreational bodybuilders.[21][22] WP

Pharmacology

Pharmacology

The tertiary butyl group in salbutamol makes it more selective for β₂ receptors, which are the predominant receptors on the bronchial smooth muscles. Activation of these receptors causes adenylyl cyclase to convert ATP to cAMP, beginning the signalling cascade that ends with the inhibition of myosin phosphorylation and lowering the intracellular concentration of calcium ions (myosin phosphorylation and calcium ions are necessary for muscle contractions). The increase in cAMP also inhibits inflammatory cells in the airway, such as basophils, eosinophils, and most especially mast cells, from releasing inflammatory mediators and cytokines. Salbutamol and other β₂ receptor agonists also increase the conductance of channels sensitive to calcium and potassium ions, leading to hyperpolarisation and relaxation of bronchial smooth muscles.[23–26] WP

Salbutamol is either filtered out by the kidneys directly or is first metabolised into the 4′-O-sulfate, which is excreted in the urine.[4] WP

Research

Research

Salbutamol has been studied in subtypes of congenital myasthenic syndrome associated with mutations in Dok-7.[27] WP

It has also been tested in a trial aimed at treatment of spinal muscular atrophy; it is speculated to modulate the alternative splicing of the SMN2 gene, increasing the amount of the SMN protein, the deficiency of which is regarded as a cause of the disease.[28][29] WP

Albuterol increases energy expenditure by 10 to 15 per cent at a therapeutic dose for asthma and around 25 per cent at a higher, oral dose. In several human studies, albuterol increased lean body mass, reduced fat mass, and caused lipolysis; it has been studied for use as an anti-obesity and anti-muscle wasting medication when taken orally.[30][31] WP

History

History

Salbutamol was discovered in 1966, by a research team led by David Jack at the Allen and Hanburys laboratory (now a subsidiary of Glaxo) in Ware, Hertfordshire, England, and was launched as Ventolin in 1969.[32] WP

The 1972 Munich Olympics were the first Olympics where anti-doping measures were deployed, and at that time β₂ agonists were considered to be stimulants with high risk of abuse for doping. Inhaled salbutamol was banned from those games, but by 1986 was permitted (although oral β₂ agonists were not). After a steep rise in the number of athletes taking β₂ agonists for asthma in the 1990s, Olympic athletes were required to provide proof that they had asthma in order to be allowed to use inhaled β₂ agonists.[33] WP

In early 2020, the US Food and Drug Administration (FDA) approved the first generic versions of major albuterol sulfate inhaler brands, Perrigo Pharmaceutical's generic of ProAir HFA in February 2020 and Cipla Limited's generic of Ventolin HFA in April 2020.[34][35] WP

Legal status

Names

Salbutamol is the international nonproprietary name (INN) while albuterol is the United States Adopted Name (USAN). The drug is usually manufactured and distributed as the sulfate salt (salbutamol sulfate).[36] WP

It was first sold by Allen & Hanburys (UK) under the brand name Ventolin, and has been used for the treatment of asthma ever since. The drug is marketed under many names.[1][37] WP

Doping

As of 2011 there was no evidence that an increase in physical performance occurs after inhaling salbutamol, but there are various reports for benefit when delivered orally or intravenously. In spite of this, salbutamol required "a declaration of Use in accordance with the International Standard for Therapeutic Use Exemptions" under the 2010 WADA prohibited list. This requirement was relaxed when the 2011 list was published to permit the use of "salbutamol (maximum 1600 micrograms over 24 hours) and salmeterol when taken by inhalation in accordance with the manufacturers' recommended therapeutic regimen."[38–41] WP

Abuse of the drug may be confirmed by detection of its presence in plasma or urine, typically exceeding 1,000 ng/mL. The window of detection for urine testing is on the order of just 24 hours, given the relatively short elimination half-life of the drug, estimated at between 5 and 6 hours following oral administration of 4 mg.[24][42][43][44] WP

Chemistry

Formula

C13H21NO3 PC

CAS number

18559-94-9 PC

Molar mass (g/mol)

239.31 PC

IUPAC name (computed by PubChem)

4-[2-(tert-butylamino)-1-hydroxyethyl]-2-(hydroxymethyl)phenol PC

SMILES

CC(C)(C)NCC(C1=CC(=C(C=C1)O)CO)O PC

InChIKey

NDAUXUAQIAJITI-UHFFFAOYSA-N PC

PubChem CID

2083

Harm reduction information

No harm reduction data is on file for this compound yet. That means no dose, timing or combination data from PsychonautWiki or TripSit. Please don't guess a dose from similar compounds. If you have taken it and feel unwell, contact emergency services or a poison control center.

User reports

Pop culture

No references added yet.

Sources

1. Other Salbutamol
2. Other Albuterol
3. Journal / agency Mahoney BA, Smith WA, Lo DS, Tsoi K, Tonelli M, Clase CM. Emergency interventions for hyperkalaemia. The Cochrane Database of Systematic Reviews. April 2005. doi:10.1002/14651858.CD003235.pub2 · PMID 15846652 · PMC6457842
4. Journal / agency Starkey ES, Mulla H, Sammons HM, Pandya HC. Intravenous salbutamol for childhood asthma: evidence-based medicine?. Archives of Disease in Childhood. September 2014. doi:10.1136/archdischild-2013-304467 · PMID 24938536
5. Other Thereaputic Goods Administration. Prescribing medicines in pregnancy database. 19 December 2018
6. Other Landau R. Pharmaceutical innovation: revolutionizing human health. 1999
7. Other Fischer J, Ganellin CR. Analogue-based Drug Discovery. 2006
8. Other The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). 2023
9. Other The Top 300 of 2023
10. Other Albuterol Drug Usage Statistics, United States, 2014 – 2023
11. Other Hatfield H. Asthma: The Rescue Inhaler -- Now a Cornerstone of Asthma Treatment
12. Other Australian Medicines Handbook. 2004
13. Journal / agency Allen NM, Hacohen Y, Palace J, Beeson D, Vincent A, Jungbluth H. Salbutamol-responsive fetal acetylcholine receptor inactivation syndrome. Neurology. February 2016. doi:10.1212/WNL.0000000000002382 · PMID 26791147 · PMC4762416
14. Journal / agency Allen NM, O'Rahelly M, Eymard B, Chouchane M, Hahn A, Kearns G, Kim DS, Byun SY, Nguyen CE, Schara-Schmidt U, Kölbel H, Marina AD, Schneider-Gold C, Roefke K, Thieme A, Van den Bergh P, Avalos G, Álvarez-Velasco R, Natera-de Benito D, Cheng MH, Chan WK, Wan HS, Thomas MA, Borch L, Lauzon J, Kornblum C, Reimann J, Mueller A, Kuntzer T, Norwood F, Ramdas S, Jacobson LW, Jie X, Fernandez-Garcia MA, Wraige E, Lim M, Lin JP, Claeys KG, Aktas S, Oskoui M, Hacohen Y, Masud A, Leite MI, Palace J, De Vivo D, Vincent A, Jungbluth H. The emerging spectrum of fetal acetylcholine receptor antibody-related disorders (FARAD). Brain: A Journal of Neurology. October 2023. doi:10.1093/brain/awad153 · PMID 37186601 · PMC10545502
15. Other Inhalation Therapy of Airway Disease
16. Other Plumb DC. Plumb's Veterinary Drug Handbook. 2011
17. Other Clarke KW, Trim CM. Veterinary Anaesthesia E-Book. 28 June 2013
18. Other Sobczak BR. Clinical Veterinary Advisor Dogs and Cats. 9 December 2014
19. Other British National Formulary. March 2008
20. Other Primary care networks incentivised to switch patients to more environmentally friendly inhalers. 3 September 2021
21. Journal / agency Jessen S, Reitelseder S, Kalsen A, Kreiberg M, Onslev J, Gad A, Ørtenblad N, Backer V, Holm L, Bangsbo J, Hostrup M. β₂-Adrenergic agonist salbutamol augments hypertrophy in MHCIIa fibers and sprint mean power output but not muscle force during 11 weeks of resistance training in young men. Journal of Applied Physiology. March 2021. doi:10.1152/japplphysiol.00553.2020 · PMID 33357007
22. Journal / agency Ip EJ, Doroudgar S, Lau B, Barnett MJ. Anabolic steroid users' misuse of non-traditional prescription drugs. Research in Social & Administrative Pharmacy. August 2019. doi:10.1016/j.sapharm.2018.07.003 · PMID 31303195
23. Other Lemke TL, Williams DA, Roche VF, Zito SW. Foye's Principles of Medicinal Chemistry. 2013
24. Other Albuterol Sulfate
25. Other Papich MG. Saunders Handbook of Veterinary Drugs. 2007
26. Journal / agency Albuterol - Medical Countermeasures Database. 28 April 2017
27. Journal / agency Liewluck T, Selcen D, Engel AG. Beneficial effects of albuterol in congenital endplate acetylcholinesterase deficiency and Dok-7 myasthenia. Muscle & Nerve. November 2011. doi:10.1002/mus.22176 · PMID 21952943 · PMC3196786
28. Journal / agency Van Meerbeke JP, Sumner CJ. Progress and promise: the current status of spinal muscular atrophy therapeutics. Discovery Medicine. October 2011. PMID 22031667
29. Journal / agency Lewelt A, Newcomb TM, Swoboda KJ. New therapeutic approaches to spinal muscular atrophy. Current Neurology and Neuroscience Reports. February 2012. doi:10.1007/s11910-011-0240-9 · PMID 22134788 · PMC3260050
30. Journal / agency Hostrup M, Onslev J. The beta₂-adrenergic receptor – a re-emerging target to combat obesity and induce leanness?. The Journal of Physiology. March 2022. doi:10.1113/JP281819 · PMID 34676534
31. Journal / agency Hostrup M, Jacobson GA, Jessen S, Lemminger AK. Anabolic and lipolytic actions of beta₂ -agonists in humans and antidoping challenges. Drug Testing and Analysis. May 2020. doi:10.1002/dta.2728 · PMID 31960603
32. Other Sir David Jack, who has died aged 87, was the scientific brain behind the rise of the pharmaceuticals company Glaxo. 17 November 2011
33. Journal / agency Fitch KD. beta2-Agonists at the Olympic Games. Clinical Reviews in Allergy & Immunology. 2006. doi:10.1385/CRIAI:31:2:259 · PMID 17085798
34. Journal / agency FDA approves first generic of ProAir HFA. 24 February 2020
35. Journal / agency FDA Approves First Generic of a Commonly Used Albuterol Inhaler to Treat and Prevent Bronchospasm. 8 April 2020
36. Journal / agency Salbutamol
37. Journal / agency Ventolin remains a breath of fresh air for asthma sufferers, after 40 years. The Pharmaceutical Journal
38. Journal / agency Pluim BM, de Hon O, Staal JB, Limpens J, Kuipers H, Overbeek SE, Zwinderman AH, Scholten RJ. β₂-Agonists and physical performance: a systematic review and meta-analysis of randomized controlled trials. Sports Medicine. January 2011. doi:10.2165/11537540-000000000-00000 · PMID 21142283
39. Journal / agency Davis E, Loiacono R, Summers RJ. The rush to adrenaline: drugs in sport acting on the beta-adrenergic system. British Journal of Pharmacology. June 2008. doi:10.1038/bjp.2008.164 · PMID 18500380 · PMC2439523
40. Other The 2010 Prohibited List International Standard
41. Other The 2011 Prohibited List International Standard
42. Other Baselt RC. Disposition of Toxic Drugs and Chemicals in Man. 2008
43. Journal / agency Bergés R, Segura J, Ventura R, Fitch KD, Morton AR, Farré M, Mas M, de La Torre X. Discrimination of prohibited oral use of salbutamol from authorized inhaled asthma treatment. Clinical Chemistry. September 2000. doi:10.1093/clinchem/46.9.1365 · PMID 10973867
44. Journal / agency Schweizer C, Saugy M, Kamber M. Doping test reveals high concentrations of salbutamol in a Swiss track and field athlete. Clinical Journal of Sport Medicine. September 2004. doi:10.1097/00042752-200409000-00018 · PMID 15377972

Text and values on this page are quoted from Wikipedia (CC BY-SA 4.0), PubChem (public domain). Each value links to the exact revision it came from.